NextCure (NXTC) vs Rockwell Medical (RMTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NextCure (NXTC) has outperformed Rockwell Medical (RMTI) over the past year, losing 1.0% versus a loss of 34.8%. Over five years, RMTI leads with a -88.0% price change compared with -93.5% for NXTC. NextCure is the larger company by market cap ($32.9 million vs $31.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NXTC | RMTI |
|---|---|---|
| Share price | $7.18 | $7.89 |
| Market cap | $32.87M | $31.80M |
| 1-day change | +5.90% | -1.62% |
| YTD return | -52.22% | -4.94% |
| 1-year return | -1.02% | -34.79% |
| 5-year return | -93.53% | -88.05% |
| Forward P/E | — | 112.71 |
| EPS (TTM) | $-8.71 | $-1.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.74 | $12.90 |
| 52-week low | $1.55 | $4.89 |
| Distance from 52-week high | -54.38% | -38.84% |
| Analyst consensus | none | none |
| Avg. price target upside | +178.55% | +153.49% |
| Average volume | 2.11M | 26.44K |
| Shares outstanding | 4.58M | 4.03M |
| Employees | 40 | 157 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NXTC has outperformed RMTI by 33.8 percentage points over the past year.
About NextCure
NXTC stock →NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
About Rockwell Medical
RMTI stock →Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.
Health Care · Biotechnology: Pharmaceutical Preparations · 157 employees
NXTC vs RMTI FAQ
Which is bigger, NextCure or Rockwell Medical?
NextCure (NXTC) is larger, with a market capitalization of $32.87M compared with $31.80M for Rockwell Medical (RMTI).
Which stock has performed better over the past year, NXTC or RMTI?
NXTC returned -1.02% over the past 12 months, compared with -34.79% for RMTI (price return, excluding dividends). Past performance does not predict future results.
Are NextCure and Rockwell Medical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.